|
Cybin Corp. is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.
The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and
nutraceutical industries.
In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods,
the isolation of chemical compounds, new drug formulations and protocol regimes.
Investment Considerations:
- Cybin is a leading Canada-based mushroom life sciences company focused on psychedelic medicines and nutraceutical products.
- The company has two operating divisions – Serenity Life Sciences (psychedelic pharmaceutical products) and Natures Journey Inc. (medicinal nutraceutical products).
- Members of Cybin’s experienced management team have collectively run multiple clinical trials and helped facilitate over $1 billion in pharmaceutical sales.
- The company recently announced a strategic partnership with the Toronto Centre for Psychedelic Science.
- Cybin is currently marketing a range of fungi-based supplements under its Journey brand aimed at breaking into the global non-psychedelic legal supplement market, which is valued at $25 billion annually and growing at a 9% year-over-year rate.
- The company has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year.
- Cybin recently entered an amalgamation agreement that is expected to result in the reverse takeover of Clarmin Exploration Inc. by Cybin.
- To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.
|
